trxc - From the CC this morning, Rick Wise of Stifel sounded surprised at the two indications applied for and cleared. GYN and colorectal are large and more complex indications so it suggest company will have an easy road ahead in expanding to other indications. CEO doesn't plan to go head to head with ISRG on accounts although some current EU installations are ISRG users. They plan to go after existing LAP procedures (ISRG goes after conversion of open to robotics) that are not using ISRG, probably because of cost vs reimbursement issues. I think any administrator will look at Senhance if they are going through a replacement cycle as economics is just better. Note on Rick Wise, he was on the ISRG story when they were still beta testing. I am not sure what fair value at this stage is given the lack of sales data. I was guessing 1B market cap for now but Wise's Q&A suggest I am too conservative longer term.
Sheesh, market cap is already pushing 900M as I was typing this. What a rocket.
News 
Market Data 
Discover 
